DaviesCPanHGodwinJ. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet2013;381:805–816.
GrayRGReaDHandleyK. aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 in 6,953 women with early breast cancer [abstract]. J Clin Oncol2013;31(Suppl):Abstract 5.
GossPEIngleJNMartinoS. Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole. Ann Oncol2013;24:355–361.
KwonJSPansegrauGNourmoussaviM. Long-term consequences of ovarian ablation for premenopausal breast cancer. Breast Cancer Res Treat2016;157:565–573.
HaldarKGiamougiannisPWilsonCCrawfordR. Laparoscopic salpingo-oophorectomy for ovarian ablation in women with hormone-sensitive breast cancer. Int J Gynaecol Obstet2011;113:222–224.
Healthcare Bluebook. Fair Price search tool. Available at: https://healthcarebluebook.com/page_ConsumerFront.aspx. Accessed February 28 2017.
KingJTJrTsevatJLaveJRRobertsMS. Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation. Med Decis Making2005;25:667–677.
GossPEIngleJNMartinoS. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst2005;97:1262–1271.
ColleoniMSunZPriceKN. Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the International Breast Cancer Study Group trials I to V. J Clin Oncol2016;34:927–935.
PanHGrayRGDaviesC. Predictors of recurrence during years 5-14 in 46,138 women with ER+ breast cancer allocated 5 years only of endocrine therapy (ET) [abstract]. J Clin Oncol2016;34(Suppl):Abstract 505.
Social Security Administration. Actuarial Life Table. Available at: http://www.socialsecurity.gov/OACT/STATS/table4c6.html. Accessed March 9 2017.
ParkerWHFeskanichDBroderMS. Long-term mortality associated with oophorectomy compared with ovarian conservation in the Nurses' Health Study. Obstet Gynecol2013;121:709–716.
AndersonWFKatkiHARosenbergPS. Incidence of breast cancer in the United States: current and future trends. J Natl Cancer Inst2011;103:1397–1402.
ChlebowskiRTPanKColNF. Ovarian suppression in combination endocrine adjuvant therapy in premenopausal women with early breast cancer. Breast Cancer Res Treat2017;161:185–190.
Ovarian ablation in early breast cancer: overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet1996;348:1189–1196.
Writing Group MembersMozaffarianDBenjaminEJ. Executive summary: heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation2016;133:447–454.
GoodRx. Available at: http://www.goodrx.com/. Accessed February 28 2017.